|
|
|
|
Vol. 59, Issue 4, 867-874, April 2001
Department of Metabolic and Cardiovascular Diseases, Novartis Institute for Biomedical Research, Summit, New Jersey (D.H., M.G., C.L.C.); and Department of Molecular Pharmacology, ISIS Pharmaceuticals, Carlsbad, California (W.G., B.P.M., R.A.M.)
| |
Abstract |
|---|
|
|
|---|
In the present study, rat cardiac myocytes were used as an in vitro ischemia/reperfusion injury model to delineate the role of c-Jun N-terminal kinase (JNK) 1 and JNK2 isoforms in ischemia/reoxygenation-induced apoptosis using an antisense approach. Exposure of rat cardiac myocytes to ischemia did not induce apoptosis as detected by staining with either acridine orange/ethidium bromide or annexin-V-fluorescein/propidium iodide. In contrast, a time-dependent increase in the number of apoptotic cells was noted after reoxygenation of ischemic myocytes, whereas the level of necrotic cells remained unaltered. Reoxygenation, but not ischemia alone, also caused a time-dependent increase in JNK activation that preceded apoptosis induction. Treatment of cardiac myocytes with antisense (AS) oligonucleotides that specifically targeted either JNK1 or JNK2 significantly reduced both mRNA and protein expression of the target isoform but had no effect on the expression of the alternate isoform. Pretreatment of cardiac myocytes with JNK1 AS, but not JNK2 AS, resulted in almost complete attenuation of reoxygenation-induced apoptosis. Furthermore, control oligonucleotides for JNK1 AS or JNK2 AS had no effect on JNK mRNA or protein expression or reoxygenation-induced apoptosis, indicating a sequence-specific mode of action. Additional studies revealed that apoptosis induced by other JNK-activating stimuli, including ceramide, heat shock, and UV irradiation, was partly suppressed after treatment with JNK1 AS but not JNK2 AS. These findings demonstrate that the JNK1 isoform plays a preferential role in apoptosis induced by ischemia/reoxygenation as well as diverse JNK-activating cellular stresses.
| |
Introduction |
|---|
|
|
|---|
Ischemia/reperfusion injury has
been identified as a major stimulus for organ dysfunction and cellular
death in several disease states including angina and myocardial
infarction (Ambrosio and Tritto, 1999
). Although timely restoration of
blood flow serves to improve myocardial viability, the reperfusion
process itself may exacerbate myocardial injury. Several mechanisms may
contribute to reperfusion injury, including postischemic inflammation,
generation of oxygen free radicals, and alterations in intracellular
calcium hemostasis (Ambrosio and Tritto, 1999
). Cardiac myocyte cell
death after ischemia/reperfusion can occur by both apoptosis and
necrosis, two distinct modes of cellular death. Although cell death
after prolonged periods of ischemia is attributable predominately to necrosis (Umansky et al., 1995
), apoptosis occurs in cells and tissues
exposed to reoxygenation after ischemia. Reperfusion after transient
myocardial ischemia activates apoptosis in cardiac myocytes grown in
culture (Laderoute and Webster, 1997
; Webster et al., 1999
) or in
animal models of myocardial ischemia/reperfusion (Gottleib et al.,
1994
; Buerke et al., 1995
).
The intracellular signaling pathways that mediate stress responses of
the myocardium have not been fully delineated. However, substantial
evidence has demonstrated that p38 mitogen-activated protein (MAP)
kinases and c-Jun N-terminal kinases (JNK) are activated in cardiac
myocytes in response to diverse cellular stresses resulting in
apoptosis. In the isolated perfused rat heart, p38 MAP kinase is
activated by ischemia and maintained during reperfusion (Bogoyevitch et
al., 1996
; Yin et al., 1997
). In contrast, activation of JNK occurs
during the reperfusion phase and not during ischemia (Bogoyevitch et
al., 1996
; Knight and Buxton, 1996
; Laderoute and Webster, 1997
; Yin et
al., 1997
; Clerk et al., 1998
). Furthermore, it has been demonstrated
in rat heart that JNK translocates to the nucleus during ischemia to be
phosphorylated during the reperfusion period (Mizukami and Yoshida,
1997
). A strong correlation between JNK activation and apoptosis
induction has been described previously in heart and kidney exposed to
ischemia/reperfusion (Yin et al., 1997
; Yue et al., 1998
). Cook et al.
(1999)
have noted an enhanced activation of JNK and p38 MAP kinase in
hearts obtained from patients with heart failure caused by ischemic
heart disease, suggesting that activation of these kinases may
contribute to the pathophysiology of the disease.
The MAP kinase family of mitogen-activated, serine/threonine kinases
comprises extracellular signal-regulated kinases, p38 MAP
kinases, and JNKs, which play important roles in diverse cellular processes. These kinase families are differentiated based on activating stimuli, substrate specificity, and distinct physiological responses (Bogoyevitch, 2000
). Whereas extracellular signal-regulated kinases participate in cell growth and differentiation, p38 MAP kinases and
JNKs play a crucial role in the cellular response to environmental stress including inflammatory cytokines, UV irradiation, heat shock,
and ischemia/reperfusion (Sugden and Clerk, 1998
). However, based on
cell type and activating stimuli, the JNK signaling pathway can also
participate in cellular processes unrelated to stress responses, such
as proliferation and differentiation (Bost et al., 1999
; Potapova et
al., 2000
). After activation by dual phosphorylation on tyrosine and
threonine residues, JNKs phosphorylate the transcription factors c-Jun,
ATF-2, and Elk-1 (Kyriakis et al., 1994
; Gupta et al., 1996
). JNKs are
alternatively known as stress-activated protein kinases (SAPKs),
although the JNK and SAPK terminology originally referred to human and
rat enzymes, respectively (see Sugden and Clerk, 1998
). Molecular
cloning has revealed three human JNK genes (JNK1,
JNK2, and JNK3) that correspond to
SAPK
, SAPK
, and SAPK
in rat.
Each of these genes produces alternatively spliced transcripts that
encode proteins of 46 and 54 kDa (Kyriakis et al., 1994
; Gupta et al.,
1995
). Although JNK1 and JNK2 are widely expressed, JNK3 is
predominately found in brain and, to a lesser extent, in heart and
testes (Mohit et al., 1995
; Gupta et al., 1996
). Although the JNK
signaling pathway is known to play a role in ischemia/reperfusion
injury, the distinct role of JNK isoforms in
ischemia/reoxygenation-induced apoptosis has not been reported
previously. The fact that the various isoforms differ in their
specificity for downstream transcription factors (Gupta et al., 1996
)
as well as in stress-induced activation (Yin et al., 1997
; Butterfield
et al., 1999
) suggests that JNK isoforms may exhibit different
physiological roles.
The aim of the present study was to examine the roles of the JNK1 and JNK2 isoforms in reoxygenation-induced apoptosis using a cardiac myocyte model of ischemia/reperfusion injury. Treatment of cells with highly specific antisense oligonucleotides targeting either JNK1 or JNK2 reduced the expression of the respective target mRNA and protein without effecting expression of the alternative isoform. Oligonucleotide-mediated reduction of JNK1 protein expression resulted in suppression of apoptosis induced by ischemia/reoxygenation whereas inhibition of JNK2 protein expression had no effect on reoxygenation-induced apoptosis. We provide additional evidence that apoptosis triggered by diverse stimuli including heat shock, UV irradiation, or ceramide is also inhibited after treatment with JNK1 AS, but not JNK2 AS.
| |
Experimental Procedures |
|---|
|
|
|---|
Preparation of Cardiac Myocytes. Cardiac myocytes were prepared from 3-day old neonatal Sprague-Dawley rats using the Neonatal Cardiomyocyte Isolation System (Worthington Biochemical Corporation, Lakewood, NJ). Cells were resuspended in basal medium Eagle (BME; Life Technologies, Grand Island, NY) supplemented with 5% newborn calf serum, 5% horse serum, 1% BME vitamin solution, 1% nonessential amino acids, 100 U/ml penicillin, and 1,000 µg/ml streptomycin, and plated onto 15 cm2 tissue culture dishes (Nalge; Nunc Corporation, Rochester, NY) for 1 h in a humidified incubator (95% air/5%CO2 at 37°C) to selectively remove contaminating nonmyocytes. Nonadherent cells were collected and replated onto Primaria (Becton-Dickinson, Franklin Lakes, NJ) culture dishes (100,000-125,000 cells/cm2) in supplemented BME. The nonmyocyte population amounted to <10% of the total cell population as determined by immunofluorescence staining with an anti-myosin antiserum (Sigma, St. Louis, MO). Spontaneously contracting cells were used for experiments at days 3 to 4 after isolation.
Exposure of Cardiac Myocytes to Ischemia/Reoxygenation and Other Apoptosis-Inducing Stresses. Ischemia was induced by replacing culture medium with 95% N2/5% CO2 pre-equilibrated, serum- and glucose-free Dulbecco's modified Eagle's medium (DMEM, Life Technologies) and placing the cells into a 37°C incubator in a humidified atmosphere perfused with 95% N2/5% CO2. Oxygen level was <1% and was monitored with a Fyrite Gas Analyzer (Bacharach, Pittsburgh, PA). After the indicated time periods of ischemia, cells were reoxygenated with warm, complete growth medium (containing glucose and serum) and placed at 37°C in a 95% air/5% CO2 humidified atmosphere.
In some experiments, cells were plated into 35-mm culture dishes and exposed to heat shock, UV irradiation, or ceramide. Cardiac myocytes were heat shocked by immersion into a temperature-controlled water bath (Precision Scientific, Chicago, IL) at 42°C for 30 min. UV irradiation (80 J/m2) was performed using a UV Stratalinker 1800 (Stratagene, La Jolla, CA). After exposure to heat shock or UV irradiation, the cells were incubated at 37°C in a CO2 incubator for 6 h and then analyzed for apoptosis induction. Cells were treated with 10 µM C6-ceramide for 8 h (N-hexanoylsphingosine) (Biomol Research Laboratories, Plymouth Meeting, PA) or 100 nM staurosporine for 6 h (Biomol Research Laboratories) in serum-free medium and then analyzed for apoptosis induction.Treatment with Oligonucleotides.
2'-Methoxyethyl mixed
backbone oligonucleotides were prepared as described by Monia et al.
(1996)
. These oligonucleotides contain a central phosphorothioate
deoxyoligonucleotide region that supports RNase H activity, flanked by
2'-methoxyethyl modified phosphodiester wings (Altmann et al., 1996
).
Antisense oligonucleotides complementary to JNK1 or JNK2, termed JNK1
AS or JNK2 AS, had sequences of
5'-CTCATGATGGCAAGCAATTA-3' and
5-GCTCAGTGGACATGGATGAG-3', respectively.
Control oligonucleotides to JNK1 and JNK2 had sequences of
5'-GCTCGGTGGAAATGGATCAG-3' and
5'-GCTAAGCGGTCAAGGTTGAG-3', respectively. Areas in the
sequence containing 2'-methoxyethyl modifications are indicated by
underlines. The transfection of cells was performed as described
previously (Garay et al., 2000
). Briefly, cells were incubated with
oligonucleotides at concentrations up to 1250 nM in BME containing
N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride/dioleoylphosphatidylethanolamine (Lipofectin; Life
Technologies) at a concentration of 0.25 µg/10 nmol oligonucleotide.
After 4 h, the medium was removed and replaced with supplemented
BME.
Northern Blot Analysis. Total RNA was prepared from cells by the QIAGEN RNeasy method (QIAGEN, Inc., Valencia, CA) according to the manufacturer's directions. RNA samples were quantified spectrophotometrically and electrophoresed through 1.2% agarose-formaldehyde gels and transferred to Hybond-N+ nucleic acid transfer membranes (Amersham, Piscataway, NJ) by capillary diffusion for 12 to 14 h. Immobilized RNA was cross-linked to the membrane by exposure to UV light using a Stratalinker (Stratagene, La Jolla, CA) and hybridized using 32P-labeled JNK1, JNK2, or glyceraldehyde-3-phosphate dehydrogenase specific cDNA probes which were prepared by asymmetric polymerase chain reaction using specific cDNA templates. Probes hybridized to mRNA transcripts were visualized and quantified using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA). Blots were routinely stripped of radioactivity by boiling and reprobed with a 32P-radiolabeled glyceraldehyde-3-phosphate dehydrogenase probe to confirm equal loading.
Western Blot Analysis. For Western blot analysis, cells were grown in 60 mm Primaria culture dishes at a density of 125,000/cm2. Cells were subjected to the indicated stresses, lysed and centrifuged and total protein concentration was determined. Extracts were boiled in SDS-polyacrylamide gel electrophoresis sample buffer and proteins (30 µg/lane) were separated on a 10% SDS-polyacrylamide gel. The separated proteins were transferred to a nitrocellulose membrane and treated with blocking buffer [PBS containing 10% (w/v) dry milk (Carnation; Nestlé USA, Glendale, CA) and 0.2% Tween-20]. Membranes were probed with either anti-phospho-specific JNK antibody (1:1000 dilution, New England Biolabs, Beverly, MA) which detects only dually-phosphorylated JNK (Thr183/Tyr185), anti-JNK1 (C-17)-G antibody (1:1000 dilution, Santa Cruz Corp., Santa Cruz, CA), or anti-JNK2 (D-2) antibody (1:1000 dilution, New England Biolabs) in blocking buffer. Anti-rabbit IgG conjugated with horseradish peroxidase was used as the second antibody (1:1000 dilution, 1 h, room temperature) and immune complexes were visualized using enhanced chemiluminescence according to the manufacturer's instructions (LumiGLO reagent, New England Biolabs). Blots were quantified with the use of laser scanning densitometry.
Measurement of Apoptosis and Necrosis.
Cells were examined
for morphological features of apoptosis (chromatin condensation and
fragmentation) and necrosis by fluorescence microscopy using acridine
orange and ethidium bromide uptake as described previously (Garay et
al., 2000
). Cardiomyocytes were plated into 1-well Permanox chamber
slides (Nalge; 100,000 cells/chamber) or 35-mm culture dishes in 2 ml
of growth media. After exposure to ischemia or ischemia/reoxygenation,
medium was aspirated from the cells and 50 µl of a 1:1 stock solution
of ethidium bromide and acridine orange was added to 1 ml of media and
a coverslip was attached to the cells. Treated cells were quantified by
fluorescence microscopy according to the following descriptions: normal
nuclei (bright green chromatin with organized structure), early
apoptotic (bright green chromatin that is highly condensed or
fragmented), late apoptotic (bright orange chromatin that is highly
condensed or fragmented), or necrotic (bright orange chromatin with
organized structure). At least 200 cells from randomly selected fields
were counted and quantified for each data point. The apoptotic index [percentage of apoptotic (or necrotic) cells] was calculated as number of apoptotic (or necrotic) cells/total cells counted × 100. Sample identities were concealed during scoring.
Data Analysis. Student's t test was used to determine statistical significance. Data analysis and graph generation were performed with Prism (GraphPAD Software, San Diego, CA ).
| |
Results |
|---|
|
|
|---|
Specific Inhibition of JNK1 and JNK2 mRNA and Protein Expression
after Treatment with Oligonucleotides Targeted to Either JNK1 or
JNK2.
The effect of antisense oligonucleotides targeting either
rat JNK1 (JNK1 AS) or JNK2 (JNK2 AS) on JNK isoform mRNA expression in
cultured neonatal rat cardiac myocytes was monitored by Northern blot
analysis. The expression of JNK3/SAPK
mRNA in these cells was not
detected by Northern analysis (W. Gaarde, unpublished observations).
Treatment of cardiac myocytes with increasing concentrations of JNK1 AS
or JNK2 AS resulted in a dose-dependent reduction in JNK1 or JNK2 mRNA
levels (IC50 values ~500 nM for both
oligonucleotides) (data not shown). Exposure of cardiac myocytes to
750-1250 nM JNK1 AS resulted in a significant inhibition of JNK1 mRNA
while having no effect on JNK2 mRNA (Fig.
1). Conversely, 750-1250 nM JNK2 AS
significantly inhibited JNK2 mRNA expression, whereas the expression of
JNK1 remained unchanged (Fig. 1). Moreover, JNK mRNA expression was not
decreased after exposure to a JNK1 mismatch control oligonucleotide
indicating that the antisense oligonucleotides reduce JNK mRNA levels
in a sequence-specific manner (Fig. 1).
|
|
Induction of Apoptosis by Ischemia/Reoxygenation in Rat Cardiac
Myocytes.
Time course experiments for reoxygenation-induced
apoptosis were performed to determine an appropriate time point at
which to evaluate the effect of the oligonucleotides targeted to JNK isoforms. Cardiac myocytes were subjected to increasing periods of
ischemia followed by 15 h of reoxygenation and apoptosis was assessed using fluorescent DNA binding dyes. Few apoptotic cells (5.5 ± 0.6%) were observed in cardiac myocytes grown under
normoxic conditions and this number was not significantly altered after exposure to increasing periods of ischemia (Fig.
3A). In contrast, when cells were exposed
to ischemia, ranging from 30 min to 8 h and then reoxygenated for
15 h, the number of apoptotic cells increased significantly (Fig.
3A). Subsequent experiments examined the time course for both apoptosis
and necrosis after exposure of cardiac myocytes to either 4 h of
ischemia or 4 h of ischemia followed by reoxygenation (up to
24 h). Increasing periods of reoxygenation resulted in a
time-dependent increase in the number of apoptotic cells that reached
19% at 24 h postreoxygenation (Fig. 3B). In contrast, there was
no difference in the level of necrotic cells between cultures subjected
to normoxia, ischemia only, or ischemia/reoxygenation, suggesting that
the predominant form of cell death is apoptosis in this model (Fig.
3B). The augmentation of apoptotic, but not necrotic cells, after
reoxygenation of ischemic cardiac myocytes was confirmed using
annexin-V-fluorescein and propidium iodide, which detect early
apoptotic and necrotic cells, respectively. (Fig. 3C). Exposure of
cardiac myocytes to 4 h ischemia followed by 4 h
reoxygenation resulted in 31 ± 5% apoptotic cells as detected by
annexin-V-fluorescein staining.
|
Induction of JNK Activation by Ischemia/Reoxygenation in Rat
Cardiac Myocytes.
JNK phosphorylation was investigated under the
same conditions of 4 h ischemia followed by increasing periods of
reoxygenation using an anti-active JNK antibody that detects the dual
phosphorylated active forms of both p46-JNK and p54-JNK.
Phosphorylation of JNK was not detected in cells exposed to up to
24 h of ischemia, which is in agreement with previous reports
(Mackay and Mochly-Rosen, 1999
; Garay et al., 2000
). Phosphorylation of
JNK was observed within 15 min of reoxygenation; this phosphorylation
peaked at 2 h postreoxygenation and then decreased significantly
by 4 h (Fig. 4A). Quantitative
analysis of Western blots by densitometry revealed a ~7-fold and
8-fold increase in phosphorylated p46-JNK and p54-JNK, respectively,
observed at 2 h postreoxygenation compared with cells exposed to
4 h of ischemia only (Fig. 4B). The total level of JNK, as
detected by an antibody that measures all JNK isoforms, regardless of
the phosphorylation state, remained constant throughout the entire
period of reoxygenation (data not shown). In some cardiac myocyte
preparations, the anti-active JNK antibody, as well as a
non-isoform-specific JNK antibody, detected an additional band
migrating at ~48 kDa (Fig. 4A and W. Gaarde, unpublished observations) whereas this additional band was not detected using specific JNK1 or JNK2 antibodies (Fig. 2, A and B). Although the identity of this band is unknown, it may correspond to JNK3/SAPK
, which is known to migrate at 49 kDa (Mohit et al., 1995
; Butterfield et
al., 1997
). Treatment of cardiac myocytes with either JNK1 AS or JNK2
AS followed by ischemia/reoxygenation resulted in a marked attenuation
of JNK phosphorylation, whereas the JNK1 mismatch control
oligonucleotide had no effect (Fig. 4C).
|
Effect of Oligonucleotides Targeting JNK1 or JNK2 on Apoptosis
Induced by Ischemia/Reoxygenation and Other JNK-Activating
Stresses.
To delineate the contribution of JNK isoforms to
reoxygenation-induced apoptosis, rat cardiac myocytes were treated with
JNK1 AS, JNK2 AS, or a mismatch oligonucleotide for 48 h before
exposure to ischemia/reoxygenation. As noted previously, a similar
percentage of apoptotic cells was observed after exposure of cardiac
myocytes to either normoxia or 4 h of ischemia (Fig.
5A). However, when these ischemic cells
were reoxygenated for 4 h, a significant increase in the number of
apoptotic cells was observed (Fig. 5A). Pretreatment of cardiac
myocytes with JNK1 AS resulted in a significant attenuation of
reoxygenation-induced apoptosis. An 86 ± 6% (n = 3) and 76 ± 9% (n = 3) decrease in the number of
apoptotic cells was noted after treatment with 1000 nM or 1250 nM JNK1
AS, respectively (Fig. 5A). In contrast, treatment of cardiac myocytes
with JNK2 AS or a mismatch control oligonucleotide had no effect on the number of apoptotic cells after reoxygenation (Fig. 5A). Using annexin-V-fluorescein staining, a similar reduction in
reoxygenation-induced apoptosis was observed in JNK1 AS-treated cells,
but not JNK2 AS-treated cells (data not shown). To delineate whether
inhibition of JNK1 actually prevents apoptotic cell death or merely
delays its onset, apoptosis was measured after longer periods of
reoxygenation after ischemia. For these experiments, cardiac myocytes
were treated with 1000 nM JNK1 AS and then exposed to 4 h of
ischemia followed by either 4 or 72 h of reoxygenation. As shown
in Fig. 5B, the number of apoptotic cells was significantly reduced in
the JNK1 AS-treated cells after either 4 or 72 h of reoxygenation,
suggesting that cell death is prevented by pretreatment with the JNK1
oligonucleotide. Under these experimental conditions, the level of
necrotic cells was not significantly increased in JNK1 AS-treated cells
reoxygenated for 72 h (data not shown).
|
|
| |
Discussion |
|---|
|
|
|---|
In the present study, an antisense approach was used to delineate the contribution of JNK1 and JNK2 isoforms in ischemia/reoxygenation-induced apoptosis. Treatment of cardiac myocytes from neonatal rats with antisense oligonucleotides targeted to either rat JNK1 or JNK2 specifically reduced the mRNA and protein expression of the respective JNK isoform in a target-selective manner. Antisense oligonucleotide-mediated reduction of JNK1 protein expression inhibited reoxygenation-induced apoptosis whereas suppression of JNK2 protein expression had no effect on reoxygenation-induced cell death, demonstrating that JNK1, and not JNK2, plays a critical role in reoxygenation-induced apoptosis. Furthermore, apoptosis induced by other JNK-activating stresses, including ceramide, heat shock, or UV irradiation, was also suppressed by the antisense oligonucleotide targeting JNK1.
Exposure of ischemic tissues to reoxygenation greatly augments tissue
damage and the JNK signaling cascade has been implicated as playing a
pathological role in this process. Reoxygenation after ischemia induces
both JNK activation and apoptosis using perfused rat heart (Bogoyevitch
et al., 1996
; Knight and Buxton 1996
; Clerk et al., 1998
) and primary
cardiac myocytes (Laderoute and Webster, 1997
; Webster et al., 1999
).
Two previous studies have measured both apoptosis and JNK activation
concurrently in ischemic/reperfused heart and reported a good
correlation between these two processes (Yin et al., 1997
; Yue et al.,
1998
). In the present study, apoptosis was observed after
ischemia/reoxygenation but, not with ischemia alone, as assayed using
methods which detect nuclear condensation and cell-surface
phosphatidylserine exposure. A larger proportion of apoptotic cells
(31 ± 5%) was detected by annexin-V-fluorescein staining, when
compared with ethidium bromide/acridine orange staining (20 ± 1.5%), consistent with the fact that the binding of
annexin-V-fluorescein to translocated phosphatidylserine on the cell
surface measures an early apoptotic event (Van Engeland et al., 1998
).
Although a slight increase in apoptotic cells was noted after 2 h
of reoxygenation, a significant increase in apoptosis was not detected
until 4 h after reoxygenation. The time course for JNK activation,
which occurred rapidly and peaked at 2 h after reoxygenation,
preceded apoptosis induction. The small percentage of necrotic cells
noted in normoxic or ischemic myocyte cultures was not significantly
altered after reoxygenation, indicating that the predominant mode of
cell death in this cardiac myocyte model is apoptosis. It should be
noted that nonmyocyte cells in the primary culture may also contribute
to apoptosis induced by ischemia/reoxygenation.
This is the first study to investigate the contribution of JNK1 and
JNK2 to reoxygenation-induced cell injury. Treatment of cardiac
myocytes with specific antisense oligonucleotides targeted to either
JNK1 (JNK1 AS) or JNK2 (JNK2 AS) significantly reduced both mRNA and
protein expression of the target JNK isoform but had no effect on the
expression of the alternate isoform. Moreover, control oligonucleotides
for JNK1 AS or JNK2 AS had no effect on JNK protein expression or
reoxygenation-induced apoptosis, indicating a sequence-specific mode of
action. Ablation of JNK1 protein expression by JNK1 AS treatment
resulted in almost complete suppression of reoxygenation-induced
apoptosis. In contrast, there was no effect on reoxygenation-induced
apoptosis in JNK2 AS-treated cells. These data indicate that JNK1, but
not JNK2, is the predominant isoform involved in reoxygenation-induced
apoptosis in cardiac myocytes. Previously, we demonstrated that
inhibition of JNK protein expression by a JNK1 antisense
oligonucleotide inhibits hypoxia-mediated apoptosis in human kidney
cells although the oligonucleotide directed against human JNK1, in
contrast to those used in the present study, did not display JNK
isoform-specific inhibition (Garay et al., 2000
). Treatment of cardiac
myocytes with JNK1 AS suppressed apoptotic cell death both at 4 and
72 h after reoxygenation, suggesting that JNK1 AS prevented, not
just delayed, the apoptotic response to reoxygenation. The percentage
of necrotic cells was not augmented at either reoxygenation time,
indicating that the cells were not dying through an alternate mode of
cell death. In the present study, the majority of JNK1 AS-treated
cardiac myocytes exposed to ischemia/reoxygenation were viable, as
detected by Trypan Blue exclusion, and were contracting synchronously.
Nonetheless, further experimentation is needed to determine whether
suppression of apoptosis by signal transduction inhibitors, such as
JNK1 AS, results in a surviving myocyte population that exhibits normal cardiac function.
The JNK signaling cascade is also activated by diverse cellular
stresses including proinflammatory cytokines (Guo et al., 1998
),
ultraviolet irradiation (Chen et al., 1996
; Tournier et al., 2000
;
Zanke et al., 1996
), heat shock (Zanke et al., 1996
) and ceramide
(Hernandez et al., 2000
). Stress-induced JNK activation and apoptosis
has also been noted in cardiac myocytes (Clerk et al., 1998
; Webster et
al., 1999
). In the present study, we show that exposure of rat cardiac
myocytes to heat shock, UV irradiation or ceramide results in both JNK
activation and apoptosis. More importantly, pretreatment of cells with
JNK1 AS, but not JNK2 AS, resulted in almost complete protection of
ceramide-induced apoptosis while apoptosis induced by heat shock or UV
irradiation was only partly suppressed. A dominant negative JNK1 mutant
resulted in partial protection against UV irradiation-induced apoptosis in small cell tumor cells (Butterfield et al., 1997
) while complete suppression against apoptosis was observed in embryonic kidney cells
(Chen et al., 1996
). The partial suppression of apoptosis induced by
heat shock or UV irradiation in the present study may occur because the
cardiac myocytes were exposed to a maximal exposure of stress and
because these cellular stresses also activate p38 MAP kinases (Force
and Bonventre, 1998
; Sugden and Clerk, 1998
). Not surprisingly, JNK1 AS
pretreatment did not protect against apoptosis induced by the protein
kinase C inhibitor staurosporine, which does not activate JNK. Taken
together with the inhibition of ischemia/reoxygenation-induced
apoptosis, these data suggest that the JNK1 isoform plays an important
and preferential role in apoptosis induced by a variety of
JNK-activating cellular stresses. A specific function for JNK isotypes
in stress-induced apoptosis has been investigated in only a few recent
studies, most notably in neurons and tumor cells. Using inhibitory JNK1
mutants or antisense oligonucleotides, JNK1, but not JNK2, was found to
be the predominant isoform involved in apoptosis of tumor cells induced
by either an antitumor drug (Seimiya et al., 1997
) or UV irradiation
(Butterfield et al., 1997
). Tournier et al. (2000)
demonstrated that
fibroblasts derived from mice lacking the JNK1 and JNK2 genes were
protected against UV radiation-induced cell death. Suppression of
stress-induced apoptosis in JNK1 AS-treated myocytes may be a
consequence of JNK1 pathway blockade and unchecked activation of
survival-promoting proteins such as the Bcl-2 family or survival
signaling pathways (e.g., the PI 3-kinase/Akt axis). Indeed, Mockridge
et al. (2000)
have recently demonstrated that Akt is phosphorylated
during reoxygenation after ischemia/reoxygenation but not during
ischemia alone in rat cardiomyocytes. Furthermore, JNK regulates Bcl-2
via phosphorylation of the loop region, which renders Bcl-2
inactive (Maundrell et al., 1997
).
In summary, we have used highly specific antisense oligonucleotides targeted to either JNK1 or JNK2 to delineate isoform-specific functions in rat cardiac myocyte apoptosis induced by a variety of stress stimuli that activate JNK. Inhibition of JNK1 protein expression, but not that of JNK2, resulted in a significant suppression of reoxygenation-induced apoptosis, suggesting a preferential role for the JNK1 isoform in reoxygenation-induced apoptosis. These results suggest that inhibition of the JNK signaling pathway, and in particular the JNK1 isoform, may represent a useful strategy for the prevention of reperfusion injury.
| |
Footnotes |
|---|
Received September 13, 2000; Accepted January 9, 2001
Send reprint requests to: Catherine L. Cioffi, Ph.D., Department of Metabolic and Cardiovascular Diseases, Novartis Institute for Biomedical Research, 556 Morris Ave., Summit, NJ 07901. E-mail: cathy.cioffi{at}pharma.novartis.com
| |
Abbreviations |
|---|
MAP, mitogen-activated protein; JNK, c-Jun N-terminal kinase; SAPK, stress-activated protein kinase; BME, basal medium Eagle; DMEM, Dulbecco's modified Eagle's medium; AS, antisense.
| |
References |
|---|
|
|
|---|
radiation. Duration of JNK activation may determine cell death and proliferation.
J Biol Chem
271:
31929-31936
in rat mesangial cells.
J Biol Chem
273:
4027-4034
converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis.
J Biol Chem
272:
4631-4636This article has been cited by other articles:
![]() |
M. Guma, J. Rius, K. X. Duong-Polk, G. G. Haddad, J. D. Lindsey, and M. Karin Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression PNAS, May 26, 2009; 106(21): 8760 - 8765. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Xie, S. Guo, Y. Fan, H. Zhang, D. Gu, and H. Li Atrogin-1/MAFbx Enhances Simulated Ischemia/Reperfusion-induced Apoptosis in Cardiomyocytes through Degradation of MAPK Phosphatase-1 and Sustained JNK Activation J. Biol. Chem., February 27, 2009; 284(9): 5488 - 5496. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wang, W. Zhang, Y. Zhang, Y. Chen, B. Zou, B. Jiang, R. Pang, Q. Gu, L. Qiao, H. Lan, et al. c-Jun N-terminal kinase (JNK1) upregulates XIAP-associated factor 1 (XAF1) through interferon regulatory factor 1 (IRF-1) in gastrointestinal cancer Carcinogenesis, February 1, 2009; 30(2): 222 - 229. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang Mitogen-Activated Protein Kinases in Heart Development and Diseases Circulation, September 18, 2007; 116(12): 1413 - 1423. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. H. Tran, P. Andreka, C. O. Rodrigues, K. A. Webster, and N. H. Bishopric Jun Kinase Delays Caspase-9 Activation by Interaction with the Apoptosome J. Biol. Chem., July 13, 2007; 282(28): 20340 - 20350. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Milano, S. Morel, C. Bonny, M. Samaja, L. K. von Segesser, P. Nicod, and G. Vassalli A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia-reperfusion injury and infarct size in vivo Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1828 - H1835. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Lu, L. Serghides, S. N. Patel, N. Degousee, B. B. Rubin, G. Krishnegowda, D. C. Gowda, M. Karin, and K. C. Kain Disruption of JNK2 Decreases the Cytokine Response to Plasmodium falciparum Glycosylphosphatidylinositol In Vitro and Confers Protection in a Cerebral Malaria Model J. Immunol., November 1, 2006; 177(9): 6344 - 6352. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-F. Yan, E. Harja, M. Andrassy, T. Fujita, and A. M. Schmidt Protein Kinase C {beta}/Early Growth Response-1 Pathway: A Key Player in Ischemia, Atherosclerosis, and Restenosis J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A47 - A55. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cui, S.-Y. Han, C. Wang, W. Su, L. Harshyne, M. Holgado-Madruga, and A. J. Wong c-Jun NH2-Terminal Kinase 2{alpha}2 Promotes the Tumorigenicity of Human Glioblastoma Cells. Cancer Res., October 15, 2006; 66(20): 10024 - 10031. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-L. Chen, C.-F. Lin, C.-W. Chiang, M.-S. Jan, and Y.-S. Lin Lithium Inhibits Ceramide- and Etoposide-Induced Protein Phosphatase 2A Methylation, Bcl-2 Dephosphorylation, Caspase-2 Activation, and Apoptosis Mol. Pharmacol., August 1, 2006; 70(2): 510 - 517. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Shao, K. Bhattacharya, E. Hsich, L. Park, B. Walters, U. Germann, Y.-M. Wang, J. Kyriakis, R. Mohanlal, K. Kuida, et al. c-Jun N-Terminal Kinases Mediate Reactivation of Akt and Cardiomyocyte Survival After Hypoxic Injury In Vitro and In Vivo Circ. Res., January 6, 2006; 98(1): 111 - 118. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Kaiser, Q. Liang, O. Bueno, Y. Huang, T. Lackey, R. Klevitsky, T. E. Hewett, and J. D. Molkentin Genetic Inhibition or Activation of JNK1/2 Protects the Myocardium from Ischemia-Reperfusion-induced Cell Death in Vivo J. Biol. Chem., September 23, 2005; 280(38): 32602 - 32608. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cui, M. Holgado-Madruga, W. Su, H. Tsuiki, P. Wedegaertner, and A. J. Wong Identification of a Specific Domain Responsible for JNK2{alpha}2 Autophosphorylation J. Biol. Chem., March 18, 2005; 280(11): 9913 - 9920. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Yada, A. Shimamoto, C. R. Hampton, A. J. Chong, H. Takayama, C. L. Rothnie, D. J. Spring, H. Shimpo, I. Yada, T. H. Pohlman, et al. FR167653 diminishes infarct size in a murine model of myocardial ischemia-reperfusion injury J. Thorac. Cardiovasc. Surg., October 1, 2004; 128(4): 588 - 594. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. MacCorkle and T.-H. Tan Inhibition of JNK2 Disrupts Anaphase and Produces Aneuploidy in Mammalian Cells J. Biol. Chem., September 17, 2004; 279(38): 40112 - 40121. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-M. Shen, Y. Lin, S. Choksi, J. Tran, T. Jin, L. Chang, M. Karin, J. Zhang, and Z.-g. Liu Essential Roles of Receptor-Interacting Protein and TRAF2 in Oxidative Stress-Induced Cell Death Mol. Cell. Biol., July 1, 2004; 24(13): 5914 - 5922. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. G. Petrich, B. C. Eloff, D. L. Lerner, A. Kovacs, J. E. Saffitz, D. S. Rosenbaum, and Y. Wang Targeted Activation of c-Jun N-terminal Kinase in Vivo Induces Restrictive Cardiomyopathy and Conduction Defects J. Biol. Chem., April 9, 2004; 279(15): 15330 - 15338. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zou, W. Zhu, M. Sakamoto, Y. Qin, H. Akazawa, H. Toko, M. Mizukami, N. Takeda, T. Minamino, H. Takano, et al. Heat Shock Transcription Factor 1 Protects Cardiomyocytes From Ischemia/Reperfusion Injury Circulation, December 16, 2003; 108(24): 3024 - 3030. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Lysiak, Q. A. T. Nguyen, J. L. Kirby, and T. T. Turner Ischemia-Reperfusion of the Murine Testis Stimulates the Expression of Proinflammatory Cytokines and Activation of c-jun N-Terminal Kinase in a Pathway to E-Selectin Expression Biol Reprod, July 1, 2003; 69(1): 202 - 210. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Su, C. L. Cioffi, S. Stefansson, N. Mittereder, M. Garay, D. Hreniuk, and G. Liau Gene therapy vector-mediated expression of insulin-like growth factors protects cardiomyocytes from apoptosis and enhances neovascularization Am J Physiol Heart Circ Physiol, April 1, 2003; 284(4): H1429 - H1440. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-M. Yang, F. Bost, W. Charbono, N. Dean, R. McKay, J. S. Rhim, C. Depatie, and D. Mercola C-Jun NH2-terminal Kinase Mediates Proliferation and Tumor Growth of Human Prostate Carcinoma Clin. Cancer Res., January 1, 2003; 9(1): 391 - 401. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. M. W. Janssen-Heininger, R. L. Persinger, S. H. Korn, C. Pantano, B. McElhinney, N. L. Reynaert, R. C. J. Langen, K. Ckless, P. Shrivastava, and M. E. Poynter Reactive Nitrogen Species and Cell Signaling: Implications for Death or Survival of Lung Epithelium Am. J. Respir. Crit. Care Med., December 15, 2002; 166(12): S9 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Potapova, S. V. Anisimov, M. Gorospe, R. H. Dougherty, W. A. Gaarde, K. R. Boheler, and N. J. Holbrook Targets of c-Jun NH2-terminal Kinase 2-mediated Tumor Growth Regulation Revealed by Serial Analysis of Gene Expression Cancer Res., June 1, 2002; 62(11): 3257 - 3263. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.G. PETRICH, P. LIAO, and Y. WANG Using a Gene-switch Transgenic Approach to Dissect Distinct Roles of MAP Kinases in Heart Failure Cold Spring Harb Symp Quant Biol, January 1, 2002; 67(0): 429 - 438. [Abstract] [PDF] |
||||
![]() |
S. Le, T. J. Connors, and A. C. Maroney c-Jun N-terminal Kinase Specifically Phosphorylates p66ShcA at Serine 36 in Response to Ultraviolet Irradiation J. Biol. Chem., December 14, 2001; 276(51): 48332 - 48336. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Narayan, R. M. Mentzer Jr., and R. D. Lasley Annexin V staining during reperfusion detects cardiomyocytes with unique properties Am J Physiol Heart Circ Physiol, November 1, 2001; 281(5): H1931 - H1937. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||